High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said
With a plan in place, it's possible to make the most of a bear market.
NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver have been highlighted in this Investment Ideas article.
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G
The biotech is entering a new era.
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types. Speaking at a Morgan Stanley ev
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
Could cancer vaccines and AI drive the next wave of healthcare innovation?
Data centers face drama as public pushback against the AI build-out is at a high.
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
Moderna's stock is up over 100%.
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
Moderna has outpaced the healthcare sector, yet analysts remain skeptical about the stock’s outlook.
Moderna shares have soared, sunk, and soared again. You might want to consider them.
Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...
Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...
Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the mRNA pipeline. The share price return over the past 12 months is above 500%, which sets a high bar for what future progress on products and earnings needs to justify. Recent approvals for updated COVID vaccines and the first mRNA flu shot,...
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
